Saturday 17 October 2026 Export ERAS’s income statement to Excel — free account

Erasca, Inc.

In the quarter to June 2026, EPS fell 16.7% and free cash flow fell 4.67%, each against the same quarter a year earlier.

13.39 1.48 −9.95%

Follow ERAS

Alert me

Market cap: $5.2B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	1	—	1	1	—	—	—	—	—	—

Insider Ownership 20.61%

Capital & Financial Ratios $m

Market Cap 5,200.00

Revenue —

Net Income (287.22)

Free Cash Flow (252.08)

Net Debt (268.74)

Current Ratio 8.29

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 11.52

Past 5Y EPS Growth —

This Y EPS Growth (121.20%)

Next Y EPS Growth 36.24%

Next Y revenue growth —

Next 5Y EPS Growth (20.83%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 90.06%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	312	298	276	269
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	321	309	286	278

	2023	2024	2025	Q'26
Payables	2	0	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	26	31	29	34

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(7.57%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(27)	(27)	—	—	—
’25	(32)	(21)	(22)	(22)	(95)
’24	(33)	(29)	(22)	(25)	(109)
’23	(26)	(26)	(24)	(25)	(101)
’22	(26)	(27)	(24)	(26)	(103)
’21	(16)	(18)	(23)	(22)	(80)
’20	(6)	(12)	(7)	(13)	(33)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(177)	(27)	—	—	—
’25	(32)	(26)	(26)	(22)	(105)
’24	(33)	(52)	(22)	(25)	(132)
’23	(48)	(26)	(24)	(25)	(123)
’22	(35)	(32)	(26)	(27)	(120)
’21	(22)	(19)	(30)	(28)	(98)
’20	(6)	(31)	(8)	(13)	(71)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.60)	(0.14)	—	—	—
’25	(0.11)	(0.12)	(0.11)	(0.10)	(0.44)
’24	(0.23)	(0.29)	(0.11)	(0.11)	(0.69)
’23	(0.22)	(0.21)	(0.20)	(0.20)	(0.83)
’22	(0.31)	(0.30)	(0.29)	(1.06)	(1.99)
’21	(0.81)	(1.20)	(0.46)	(0.26)	(1.85)
’20	(0.20)	(0.26)	(0.50)	—	(4.83)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	11.87	3.85	1.51	1.64	1.01	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	24.47	15.71	4.60	3.45	3.80
People
People	Employees	—	—	—	—	—	123	129	126	103	103
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(12)	(102)	(123)	(243)	(125)	(162)	(125)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(12)	(102)	(123)	(243)	(125)	(162)	(125)
	Depreciation	—	—	—	0	1	1	2	(3)	(6)	(2)
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.10)	(4.83)	(1.85)	(1.99)	(0.83)	(0.69)	(0.44)
	Cash flow	—	—	—	(0.09)	(1.55)	(1.20)	(0.85)	(0.67)	(0.47)	(0.34)
	Capex	—	—	—	0.00	(1.84)	(0.28)	(0.14)	(0.14)	(0.10)	(0.03)
	Free cash flow	—	—	—	(0.09)	(3.39)	(1.49)	(0.98)	(0.82)	(0.56)	(0.37)
	Book value	—	—	—	0.42	(5.42)	6.89	3.38	2.11	1.81	1.15
	Shares, m	—	—	—	119	21	66	122	150	234	284
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(10)	(33)	(80)	(103)	(101)	(109)	(95)
	Capex	—	—	—	(1)	(39)	(19)	(17)	(22)	(23)	(10)
	Free cash flow	—	—	—	(10)	(71)	(98)	(120)	(123)	(132)	(105)
Balance, $m
Balance, $m	Working capital	—	—	—	48	106	394	396	295	277	258
	Total debt	—	—	—	4	3	19	55	—	—	—
	Net debt	—	—	—	(47)	(119)	(414)	(436)	(312)	(298)	(276)
	Shareholders’ equity	—	—	—	50	(114)	457	412	317	423	325
Returns, %
Returns, %	ROA	—	—	—	(43.38)	(112.74)	(39.21)	(47.78)	(27.48)	(36.01)	(27.72)
	ROIC	—	—	—	0.00	0.00	(185.60)	0.00	(2,039.97)	(89.66)	(179.37)
	ROE	—	—	—	18.87	159.36	(71.68)	(55.92)	(34.33)	(43.68)	(33.27)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CGON CG Oncology, Inc.	$5.5B	— (loss-making)	— (loss-making)	+2,125.00% (above 0%: growing)	n/m	−67.60% (below 0%: shrinking)	(239.24%)	(7,467.68%)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+101.55%	—	−16.56%	41.39%	0.00%

All 614 Biotechnology stocks →

Erasca, Inc. (ERAS) key facts

Erasca, Inc. (ERAS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ERAS traded at $13.39, a market capitalization of $5.2 billion.
Return on equity was −33.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.